US: FTC seeks more information on Pfizer-Allergan merger

Pfizer and Allergan said they have received a request for additional information from the US Federal Trade Commission with respect to their merger.

The FTC’s request for information extends the waiting period required under antitrust rules to 30 days, after the companies have provided the information.

The companies said the request was anticipated as part of the regulatory process and they were working with the FTC in connection with the review.

The companies continue to expect the deal to close in the second half of 2016.

Full content: The Japan Times

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.